Hongqiu Pan

机构：Jiangsu University, Affiliated Hospital of Jiangsu University · ORCID：0000-0002-7091-3230

发表论文 80 篇 · 总被引 1381 次 · h-index 21

代表论文

• Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial (2023 · EClinicalMedicine · 被引 48)
• A prospective multicenter clinical research study validating the effectiveness and safety of a chest X-ray-based pulmonary tuberculosis screening software JF CXR-1 built on a convolutional neural network algorithm (2023 · Frontiers in Medicine · 被引 14)
• High accuracy of recombinant fusion protein early secretory antigenic target protein 6‐culture filtrate protein 10 skin test for the detection of tuberculosis infection: a phase III, multi‐centered, double‐blind, hospital‐based, randomized controlled trial (2022 · International Journal of Infectious Diseases · 被引 13)
• Performance of the MeltPro TB assay as initial test for diagnosis of pulmonary tuberculosis with drug-resistance detection (2023 · Molecular Medicine · 被引 7)
• Heme Oxygenase-1 and Hemopexin Gene Polymorphisms and the Risk of Anti-Tuberculosis Drug-Induced Hepatotoxicity in China (2022 · Pharmacogenomics · 被引 4)
• Relationship between common telomere length‐related genetic variations, telomere length, and risk of antituberculosis drug‐induced hepatotoxicity in Chinese Han population: As assessed for causality using the updated Roussel Uclaf Causality Assessment Method (2023 · Fundamental and Clinical Pharmacology · 被引 3)